230 results on '"Preston RA"'
Search Results
2. Extensive Genomic Plasticity in Pseudomonas aeruginosa Revealed by Identification and Distribution Studies of Novel Genes among Clinical Isolates
- Author
-
Sujun Yu, Fen Z. Hu, Ray Wong, Robert M. Wadowsky, J. Christopher Post, Richard Dopico, Randy Keefe, Malcolm Slifkin, Benjamin Janto, John Gladitz, Nathan E. Ehrlich, Geza Erdos, Bethany Dice, Sandra Johnson, Preston Ra, Laura E. Kropp, Sameera Sayeed, Jay Hayes, Azad Ahmed, Kai Shen, Garth D. Ehrlich, Jennifer Jocz, and Patricia Antalis
- Subjects
Sequence analysis ,Molecular Sequence Data ,Immunology ,Population ,Molecular Genomics ,Genomics ,Biology ,medicine.disease_cause ,Microbiology ,Genome ,Open Reading Frames ,medicine ,Humans ,Bacteriophages ,Pseudomonas Infections ,Genomic library ,education ,Gene ,Genetics ,Genomic Library ,education.field_of_study ,Base Sequence ,Pseudomonas aeruginosa ,Gene Expression Profiling ,Sequence Analysis, DNA ,Gene expression profiling ,Infectious Diseases ,Genes, Bacterial ,Protein Biosynthesis ,Parasitology ,Genome, Bacterial - Abstract
The distributed genome hypothesis (DGH) states that each strain within a bacterial species receives a unique distribution of genes from a population-based supragenome that is many times larger than the genome of any given strain. The observations that natural infecting populations are often polyclonal and that most chronic bacterial pathogens have highly developed mechanisms for horizontal gene transfer suggested the DGH and provided the means and the mechanisms to explain how chronic infections persist in the face of a mammalian host's adaptive defense mechanisms. Having previously established the validity of the DGH for obligate pathogens, we wished to evaluate its applicability to an opportunistic bacterial pathogen. This was accomplished by construction and analysis of a highly redundant pooled genomic library containing approximately 216,000 functional clones that was constructed from 12 low-passage clinical isolates of Pseudomonas aeruginosa , 6 otorrheic isolates and 6 from other body sites. Sequence analysis of 3,214 randomly picked clones (mean insert size, ∼1.4 kb) from this library demonstrated that 348 (10.8%) of the clones were unique with respect to all genomic sequences of the P. aeruginosa prototype strain, PAO1. Hypothetical translations of the open reading frames within these unique sequences demonstrated protein homologies to a number of bacterial virulence factors and other proteins not previously identified in P. aeruginosa . PCR and reverse transcription-PCR-based assays were performed to analyze the distribution and expression patterns of a 70-open reading frame subset of these sequences among 11 of the clinical strains. These sequences were unevenly distributed among the clinical isolates, with nearly half (34/70) of the novel sequences being present in only one or two of the individual strains. Expression profiling revealed that a vast majority of these sequences are expressed, strongly suggesting they encode functional proteins.
- Published
- 2006
- Full Text
- View/download PDF
3. Fine mapping a gene for pediatric gastroesophageal reflux on human chromosome 13q14
- Author
-
Azad Ahmed, Joseph Donfack, Sandra Johnson, Fen Z. Hu, J. Christopher Post, Garth D. Ehrlich, Richard Dopico, and Preston Ra
- Subjects
Adult ,Male ,Molecular Sequence Data ,Single-nucleotide polymorphism ,Locus (genetics) ,Biology ,Polymorphism, Single Nucleotide ,DNA sequencing ,Gene Frequency ,Gene mapping ,Genetics ,Humans ,Allele ,Child ,Indel ,Gene ,Genetics (clinical) ,DNA Primers ,Expressed Sequence Tags ,Base Sequence ,Chromosomes, Human, Pair 13 ,Chromosome Mapping ,Sequence Analysis, DNA ,Transmission disequilibrium test ,Case-Control Studies ,Mutation ,Gastroesophageal Reflux ,Female ,Databases, Nucleic Acid - Abstract
We previously mapped a gene for severe pediatric gastroesophageal reflux disease ( GERD1) to a 9-cM interval on chromosome 13q14. In this report, we present the results of DNA sequencing and allelic association analyses that were done in an attempt to clone the GERD1 gene. Using a candidate transcript approach, we screened affected individuals for mutations in all transcribed regions of all genes, putative genes, and ESTs identified within the 6.2-Mb GERD1 locus based on alignments with the GenBank cDNA databases. From a total of 50 identifiable genes and 99 EST clusters in the GERD1 locus, we identified 163 polymorphisms (143 SNPs and 20 INDELs) in 21 genes and 37 ESTs. The patterns of inheritance and/or the high population frequencies of all polymorphic alleles identified in this study argued against causative relationships between any of the alleles and the GERD phenotype. Using a subset of 51 SNPs distributed throughout the GERD1 locus, we performed case-control and family (TDT) allelic association analyses on two sets of samples. The case-control study was performed with 73 GERD cases and 93 controls, and the family study was performed using 22 small families. SNP 160 (position 38,925,329 Mb, UCSChg15 map) gave a significant P value prior to multiple test correction in both the case control and family studies, while SNP168 (at 40,442,903 Mb) showed significant association after multiple test correction in the case-control sample, but was uninformative in the family sample. The results suggest that the GERD1 gene might be located near SNP160 or SNP168.
- Published
- 2004
- Full Text
- View/download PDF
4. Linkage and Association between Inflammatory Bowel Disease and a Locus on Chromosome 12
- Author
-
Sean Davis, Leilei Zhang, Preston Ra, Lara Chensny, Richard H. Duerr, Jody L. Brown, M. Michael Barmada, Garth D. Ehrlich, Daniel E. Weeks, and Christopher E. Aston
- Subjects
Male ,Linkage disequilibrium ,Locus (genetics) ,Biology ,Inflammatory bowel disease ,White People ,Genetic determinism ,Genetic linkage ,medicine ,Genetics ,Humans ,Genetics(clinical) ,Genetics (clinical) ,Chromosome 12 ,Genetic association ,Chromosomes, Human, Pair 12 ,Crohn disease ,Inflammatory Bowel Diseases ,medicine.disease ,digestive system diseases ,Ulcerative colitis ,North America ,Microsatellite ,Colitis, Ulcerative ,Female ,Lod Score ,Microsatellite Repeats ,Research Article - Abstract
Summary Genetic epidemiological studies have shown that genetic factors are important in the pathogenesis of the idiopathic inflammatory bowel diseases (IBD), Crohn disease (CD), and ulcerative colitis (UC). A genome screen in the United Kingdom found linkage of IBD to a 41-cM region of chromosome 12, surrounding D12S83. We aimed to replicate this linkage and to narrow the region of interest. Nonparametric linkage analyses at microsatellites surrounding D12S83 were performed in 122 North American Caucasian families containing 208 genotyped IBD-affected relative pairs. Transmission/disequilibrium tests (TDTs) were also performed. We confirmed that IBD is linked to chromosome 12 (peak GENEHUNTER-PLUS LOD* score 2.76 [ P = .00016] between D12S1724 and D12S90). The evidence for linkage is contributed by both the group of CD-affected relative pairs (peak GENEHUNTER-PLUS LOD* score 1.79 [ P = .0021] between D12S1724 and D12S90) and the group of UC-affected relative pairs (peak GENEHUNTER-PLUS LOD* score 1.82 [ P = .0019] at D12S335). The TDT is positive at the D12S83 locus (global χ 2 = 16.41, 6 df, P = .012). In conclusion, we have independently confirmed linkage of IBD to the chromosome 12 region that we investigated. A positive TDT at D12S83 suggests that we have greatly narrowed the chromosome 12 region that contains an IBD locus.
- Published
- 1998
- Full Text
- View/download PDF
5. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene
- Author
-
Kevin McGrath, Michael Sossenheimer, Roger A. Liddle, Preston Ra, Phillip P. Toskes, Michael C. Gorry, William Furey, Stephen P. Martin, James Christopher Post, Garth D. Ehrlich, Stephen T. Amann, Lawrence K. Gates, Charles D. Ulrich, David C. Whitcomb, and Generoso Uomo
- Subjects
Male ,Models, Molecular ,Heterozygote ,Pancreatic disease ,Protein Conformation ,Trypsinogen ,DNA Mutational Analysis ,Biology ,Arginine ,chemistry.chemical_compound ,Genetics ,medicine ,Humans ,Point Mutation ,PRSS2 ,Trypsin ,Trypsinogen activation ,Hereditary pancreatitis ,Genetic disorder ,Exons ,medicine.disease ,Pedigree ,Protein Structure, Tertiary ,Enzyme Activation ,Genes ,Pancreatitis ,chemistry ,Female ,Chromosomes, Human, Pair 7 ,Polymorphism, Restriction Fragment Length ,medicine.drug - Abstract
Hereditary pancreatitis (HP) is a rare, early-onset genetic disorder characterized by epigastric pain and often more serious complications. We now report that an Arg-His substitution at residue 117 of the cationic trypsinogen gene is associated with the HP phenotype. This mutation was observed in all HP affected individuals and obligate carriers from five kindreds, but not in individuals who married into the families nor in 140 unrelated individuals. X-ray crystal structure analysis, molecular modelling, and protein digest data indicate that the Arg 117 residue is a trypsin-sensitive site. Cleavage at this site is probably part of a fail-safe mechanism by which trypsin, which is activated within the pancreas, may be inactivated; loss of this cleavage site would permit autodigestion resulting in pancreatitis.
- Published
- 1996
- Full Text
- View/download PDF
6. Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson—Weiss syndrome
- Author
-
G J White, N A Nwokoro, H W Losken, M G Parker, Michael C. Gorry, J C Post, V K Singhal, Y Zhang, Garth D. Ehrlich, and Preston Ra
- Subjects
Male ,musculoskeletal diseases ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,RNA Splicing ,Molecular Sequence Data ,Biology ,medicine.disease_cause ,Exon ,Molecular genetics ,Genetics ,medicine ,Humans ,Point Mutation ,Receptor, Fibroblast Growth Factor, Type 2 ,Molecular Biology ,Gene ,Genetics (clinical) ,DNA Primers ,Mutation ,Base Sequence ,Fibroblast growth factor receptor 2 ,Craniofacial Dysostosis ,Point mutation ,Receptor Protein-Tyrosine Kinases ,Crouzon syndrome ,Jackson–Weiss syndrome ,Exons ,Syndrome ,General Medicine ,medicine.disease ,Receptors, Fibroblast Growth Factor ,Phenotype ,Female - Abstract
Dominant mutations in the fibroblast growth factor receptor 2 (FGFR2) gene have been recently identified as causes of four phenotypically distinct craniosynostosis syndromes, including Crouzon, Jackson-Weiss, Pfeiffer, and Apert syndromes. These data suggest that the genetics of the craniosynostosis syndromes is more complex than would be expected from their simple autosomal-dominant inheritance pattern. Identical mutations in the FGFR2 gene have been reported to cause both Pfeiffer and Crouzon syndrome phenotypes. We now report the finding of a mutation in exon IIIc of the FGFR2 gene in a kindred affected with Crouzon syndrome (C1043 to G; Ala344Gly) that is identical to the mutation previously associated with Jackson-Weiss syndrome. We also report finding in a Crouzon kindred a mutation in the 3' end of exon IIIu (formerly referred to as exon 5, exon 7, or exon U) (A878 to C; Gln289Pro) which encodes the amino terminal portion of the Ig-like III domain of the FGFR2 protein. This exon is common to both the FGFR2 and the KGFR spliceoforms of the FGFR2 gene, unlike all previously reported Crouzon mutations, which have been found only in the FGFR2 spliceoform. These findings reveal further unexpected complexity in the molecular genetics of these craniosynostosis syndromes. The data implies that second-site mutations in FGFR2 itself (outside of exon IIIc) or in other genes may determine specific aspects of the phenotypes of craniosynostosis syndromes.
- Published
- 1995
- Full Text
- View/download PDF
7. Characterization, distribution, and expression of novel genes among eight clinical isolates of Streptococcus pneumoniae
- Author
-
Laura Nistico, Nathan E. Ehrlich, Laura E. Kropp, Bethany Dice, Richard Dopico, Garth D. Ehrlich, Karen A. Barbadora, Jennifer Jocz, Randy Keefe, Jay Hayes, Fen Z. Hu, Patricia Antalis, J. Christopher Post, Benjamin Janto, Shujun Yu, Kai Shen, Preston Ra, David P. Greenberg, Azad Ahmed, and John Gladitz
- Subjects
Serotype ,Blood Platelets ,Immunology ,Molecular Sequence Data ,Virulence ,Molecular Genomics ,Biology ,medicine.disease_cause ,Microbiology ,Homology (biology) ,Bacteriocins ,Streptococcus pneumoniae ,medicine ,Humans ,Genomic library ,Cloning, Molecular ,Child ,Gene ,Genetics ,Gene Expression Profiling ,Serine Endopeptidases ,Gene expression profiling ,Infectious Diseases ,alpha-Galactosidase ,Parasitology ,Carrier Proteins ,Peptides ,Reference genome - Abstract
Eight low-passage-number Streptococcus pneumoniae clinical isolates, each of a different serotype and a different multilocus sequence type, were obtained from pediatric participants in a pneumococcal vaccine trial. Comparative genomic analyses were performed with these strains and two S. pneumoniae reference strains. Individual genomic libraries were constructed for each of the eight clinical isolates, with an average insert size of ∼1 kb. A total of 73,728 clones were picked for arraying, providing more than four times genomic coverage per strain. A subset of 4,793 clones were sequenced, for which homology searches revealed that 750 (15.6%) of the sequences were unique with respect to the TIGR4 reference genome and 263 (5.5%) clones were unrelated to any available streptococcal sequence. Hypothetical translations of the open reading frames identified within these novel sequences showed homologies to a variety of proteins, including bacterial virulence factors not previously identified in S. pneumoniae . The distribution and expression patterns of 58 of these novel sequences among the eight clinical isolates were analyzed by PCR- and reverse transcriptase PCR-based analyses, respectively. These unique sequences were nonuniformly distributed among the eight isolates, and transcription of these genes in planktonic cultures was detected in 81% (172/212) of their genic occurrences. All 58 novel sequences were transcribed in one or more of the clinical strains, suggesting that they all correspond to functional genes. Sixty-five percent (38/58) of these sequences were found in 50% or less of the clinical strains, indicating a significant degree of genomic plasticity among natural isolates.
- Published
- 2005
8. The Huygens Doppler Wind Experiment - Titan winds derived from probe radio frequency measurements
- Author
-
Bird, Mk, DUTTA ROY, R, Heyl, M, Allison, M, Asmar, Sw, Folkner, Wm, Preston, Ra, Atkinson, Dh, Edenhofer, P, Plettemeier, D, Wohlmuth, R, Iess, Luciano, and Tyler, Gl
- Published
- 2002
9. A morphological and spectral study of GPS galaxies and quasars
- Author
-
Schilizzi, RT, Tschager, W, Snellen, IAG, de Bruyn, AG, Miley, GK, Rottgering, HJA, van Langevelde, HJ, Fanti, C, Fanti, R, Hirabayashi, H, Preston, RA, and Gurvits, LI
- Subjects
SAMPLE ,POLARIZATION ,EXTRAGALACTIC RADIO-SOURCES ,YOUNG ,MAPS - Abstract
We have analysed HALCA and global VLBI data for 2021+614, the first of eleven GPS quasars and galaxies to be observed by HALCA. We show that 2021+614 is a compact symmetric object of overall size similar to 40 pc, and confirm that the speed of separation of the two dominant lobes is approximately one tenth of the speed of light. Its apparent age of less than 1000 years provides additional support for the contention that compact symmetric radio objects associated with galaxies are young radio sources and the possible precursors of the classical FR1 or FR2 radio galaxies. (C) 2000 COSPAR. Published by Elsevier Science Ltd.
- Published
- 2000
10. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis
- Author
-
William Furey, Michael C. Gorry, D Gabbaizedeh, Gates Lk, C Ulrich, Yingze Zhang, Christopher E. Aston, Garth D. Ehrlich, Preston Ra, and David C. Whitcomb
- Subjects
Male ,medicine.medical_specialty ,Pancreatic disease ,Trypsinogen ,Genetic Linkage ,Population ,Biology ,Gastroenterology ,chemistry.chemical_compound ,Recurrence ,Internal medicine ,medicine ,PRSS2 ,Humans ,Point Mutation ,Isoleucine ,education ,Hereditary pancreatitis ,education.field_of_study ,Hepatology ,Adenine ,Chromosome Mapping ,medicine.disease ,Pedigree ,Hospitalization ,Endocrinology ,chemistry ,Pancreatitis ,Zymogen activation ,Acute Disease ,Chronic Disease ,Acute pancreatitis ,Female ,Asparagine ,Chromosomes, Human, Pair 7 ,Thymine - Abstract
We recently identified a single R117H mutation in the cationic trypsinogen gene in several kindreds with an inherited form of acute and chronic pancreatitis (HP1), providing strong evidence that trypsin plays a central role in premature zymogen activation and pancreatitis. However, not all families studied have this mutation. The aim of this study was to determine the disease-causing mutation in kindreds with hereditary pancreatitis that lack the previously identified mutation.Clinical features of the HP1 kindreds were compared with those of the new kindreds (HP2), and genetic linkage analysis, screening for mutations through DNA sequencing, and screening an unaffected population were performed.The onset of symptoms was delayed and hospitalizations were fewer in HP2 compared with HP1 (P0.05). Linkage of the disease gene to chromosome 7q35 was established (logarithm of the odds, 3.73). Mutational screening identified a single A to T mutation resulting in an asparagine to isoleucine transition mutation at position 21 (N21I) in cationic trypsinogen. The mutation was absent in 94 unrelated individuals, representing 188 unique chromosomes.The identification of a second mutation in the cationic trypsinogen gene (HP2) suggests a dominant role of trypsin in premature protease activation-mediated forms of acute pancreatitis. The pathogenesis of hereditary pancreatitis also suggests that chronic pancreatitis may result from recurrent acute pancreatitis.
- Published
- 1997
11. A gene for hereditary pancreatitis maps to chromosome 7q35
- Author
-
Gates Lk, Paul G. Wood, Yingze Zhang, C Ulrich, Christopher E. Aston, Martin Sp, Wong-Chong A, David C. Whitcomb, Garth D. Ehrlich, Michael Sossenheimer, White Gj, Barua Ps, Preston Ra, and James Christopher Post
- Subjects
Chromosome 7 (human) ,Genetics ,Male ,Hereditary pancreatitis ,Hepatology ,Genetic Linkage ,Haplotype ,Gastroenterology ,Chromosome ,Chromosome Mapping ,Locus (genetics) ,Biology ,medicine.disease ,Penetrance ,Pedigree ,Phenotype ,Genes ,Pancreatitis ,Genetic linkage ,medicine ,Microsatellite ,Humans ,Chromosomes, Human, Pair 7 - Abstract
BACKGROUND & AIMS: Hereditary pancreatitis (HP) is an autosomal- dominant disorder with incomplete penetrance characterized by recurrent bouts of severe epigastric pain with onset usually at 5-10 years of age. A genetic linkage study was designed to identify the HP gene. METHODS: A 500-member pedigree was constructed from a U.S. kindred centered in eastern Kentucky and western Virginia. A genome-wide search strategy was employed using a 36-member subset of this family to determine the genetic locus for HP. Testing for linkage to microsatellite loci was performed at 20-cM intervals. RESULTS: Linkage was established between the HP phenotype and chromosome 7q in this subset of the family. Modeled as an autosomal dominant disorder with 80% penetrance, a maximal multipoint logarithm of the odds score of 4.3 was obtained using a four-point analysis consisting of markers D7S684, D7S661, D7S505, and the HP locus. Two microsatellite markers, D7S661 and D7S505, that correspond to the 7q35 region of chromosome 7 spanning a 6-cM region did not evidence obligate recombinations with HP. The centromeric and telomeric limits are defined by recombinations at D7S684 and D7S483, respectively, which generates a 19-cM locus for HP. Utilizing family members from the extended pedigree, a break in the high-risk haplotype between D7S684 and D7S661 was observed, which suggests it may be possible to exclude an additional 8 cM from the HP locus. A maximal pairwise logarithm of the odds score of 4.73 at a recombination fraction of theta at D7S684 was obtained with the addition of these extended family members. CONCLUSIONS: Linkage of HP to 7q35 represents a major advancement in our understanding of the genetic basis of this disorder. (Gastroenterology 1996 Jun;110(6):1975-80)
- Published
- 1996
12. Production of functional GLUT1 by co-expression of N- and C-terminal half molecules in Xenopus oocytes
- Author
-
Stephen A. Baldwin, Preston Ra, Sami Aj, and Charalambous Bm
- Subjects
DNA, Complementary ,Monosaccharide Transport Proteins ,Xenopus ,Gene Expression ,Biology ,In Vitro Techniques ,Biochemistry ,chemistry.chemical_compound ,Gene expression ,Molecule ,Animals ,Humans ,RNA, Messenger ,Cloning, Molecular ,Cloning ,Glucose Transporter Type 1 ,Molecular Structure ,Glucose transporter ,RNA ,biology.organism_classification ,Cell biology ,Glucose ,chemistry ,biology.protein ,Oocytes ,GLUT1 ,Female ,DNA - Published
- 1994
13. A gene for Crouzon craniofacial dysostosis maps to the long arm of chromosome 10
- Author
-
H. Wolfgang Losken, Colleen A. Morris, Preston Ra, Nassim Nouri, John J. Mulvihill, Garth D. Ehrlich, Janice M. Priest, Bronya J.B. Keats, J. Christopher Post, Robert E. Ferrell, Christopher E. Aston, and Mark R. Hurtt
- Subjects
Genetics ,Genetic Markers ,Male ,Candidate gene ,Hypoplastic maxilla ,Chromosomes, Human, Pair 10 ,Genetic Linkage ,Craniofacial Dysostosis ,PAX2 ,Chromosome Mapping ,Locus (genetics) ,Biology ,medicine.disease ,Craniosynostosis ,Pedigree ,Phenotype ,Gene mapping ,medicine ,Humans ,Female ,Craniofacial ,Lod Score ,Gene ,Genes, Dominant - Abstract
Crouzon craniofacial dysostosis (CFD) is an autosomal dominant craniofacial disorder characterized by premature craniosynostosis, shallow orbits and hypoplastic maxilla. To map the gene responsible, we have used a mapping strategy of testing for linkage to known developmental genes. Analysis of a large kindred established linkage between CFD and three loci (D10S190, D10S209 and D10S216) that span a 13 cM region on chromosome 10q. A maximum pairwise lod score of 4.42 (theta = 0) at D10S190 was obtained and the addition of a second kindred produced a combined pairwise lod score of 5.32 (theta = 0) at the same locus. The developmental gene, PAX2, located within this region, is an attractive candidate gene.
- Published
- 1994
14. Mapping a gene for dupuytren contracture in two Swedish families.
- Author
-
Hu, FZ, Nystrom, A, Ahmed, A, Dopico, R, Mossberg, I, Palmquist, M, Gladitz, J, Rayner, M, Post, JC, Preston, RA, Ehrlich, GD, Hu, FZ, Nystrom, A, Ahmed, A, Dopico, R, Mossberg, I, Palmquist, M, Gladitz, J, Rayner, M, Post, JC, Preston, RA, and Ehrlich, GD
- Published
- 2002
15. Effects of Selective vs. Nonselective Cyclooxygenase Inhibition on Dynamic Renal Potassium Excretion: A Randomized Trial
- Author
-
Preston, RA, primary, Afshartous, D, additional, and Alonso, AB, additional
- Published
- 2008
- Full Text
- View/download PDF
16. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family
- Author
-
Hu, FZ, primary, Nystrom, A, additional, Ahmed, A, additional, Palmquist, M, additional, Dopico, R, additional, Mossberg, I, additional, Gladitz, J, additional, Rayner, M, additional, Post, JC, additional, Ehrlich, GD, additional, and Preston, RA, additional
- Published
- 2005
- Full Text
- View/download PDF
17. The Design of Mass Timber Panels as Heat-Exchangers (Dynamic Insulation)
- Author
-
Salmaan Craig, Anna Halepaska, Katherine Ferguson, Preston Rains, Jacob Elbrecht, Andrew Freear, David Kennedy, and Kiel Moe
- Subjects
biogenic carbon ,carbon utilization ,low carbon materials ,integrated materials design ,mass timber construction ,sustainable construction ,Engineering (General). Civil engineering (General) ,TA1-2040 ,City planning ,HT165.5-169.9 - Abstract
Mass timber products, together with careful forestry management, could help decarbonize the construction industry. These products must be long-lasting, to safely store atmospheric carbon for decades or centuries, and multi-functional, to displace materials and equipment that are emissions-intensive. This paper shows how to optimize mass timber panels as heat-exchangers, suggesting how to eliminate insulation while simplifying HVAC systems. Test panels measured the heat-exchange in steady and transient conditions, when the ventilation was driven by a fan or by thermal buoyancy. The total heat transfer was predicted accurately by theory in all cases. Further investigation is needed to understand the possible heat-recovery effects at the exterior surface.
- Published
- 2021
- Full Text
- View/download PDF
18. Mapping of a Gene for Severe Pediatric Gastroesophageal Reflux to Chromosome 13q14
- Author
-
Garth D. Ehrlich, C. Mcgraw, J. C. Post, Jurg Ott, E. A. Pulsifer-Anderson, R. S. Stiffler, Suzanne M. Leal, Xue Wang, L. W. Kikuchi, Fen Z. Hu, Gregory C. Allen, G. J. White, Preston Ra, T. W. Self, and Mark A. Levenstien
- Subjects
medicine.medical_specialty ,Pathology ,Genotype ,Genetic Linkage ,Locus (genetics) ,Article ,Genetic determinism ,Centimorgan ,Genetic linkage ,Internal medicine ,medicine ,Humans ,Child ,Chromosome 13 ,Chromosomes, Human, Pair 13 ,business.industry ,fungi ,Haplotype ,Genetic disorder ,General Medicine ,medicine.disease ,Pedigree ,Phenotype ,Haplotypes ,Gastroesophageal Reflux ,business ,Microsatellite Repeats - Abstract
ContextGastroesophageal reflux (GER) has not previously been widely regarded as a hereditary disease. A few reports have suggested, however, that a genetic component may contribute to the incidence of GER, especially in its severe or chronic forms.ObjectiveTo identify a genetic locus that cosegregates with a severe pediatric GER phenotype in families with multiple affected members.DesignA genome-wide scan of families affected by severe pediatric GER using polymorphic microsatellite markers spaced at an average of 8 centimorgans (cM), followed by haplotyping and by pairwise and multipoint linkage analyses.SettingGeneral US community, with research performed in a university tertiary care hospital.SubjectsAffected and unaffected family members from 5 families having multiple individuals affected by severe pediatric GER, identified through a patient support group.Main Outcome MeasuresDetermination of inheritance patterns and linkage of a genetic locus with the severe pediatric GER phenotype by logarithm-of-odds (lod) score analysis, considering a lod score of 3 or greater as evidence of linkage.ResultsIn these families, severe pediatric GER followed an autosomal dominant hereditary pattern with high penetrance. A gene for severe pediatric GER was mapped to a 13-cM region on chromosome 13q between microsatellite markers D13S171 and D13S263. A maximum multifamily 2-point lod score of 5.58 and a maximum multifamily multipoint lod score of 7.15 were obtained for marker D13S1253 at map position 35 cM when presumptively affected persons were modeled as unknown (a maximum multipoint score of 4.88 was obtained when presumptively affected persons were modeled as unaffected).ConclusionThese data suggest that a gene for severe pediatric GER maps to chromosome 13q14.
- Published
- 2000
- Full Text
- View/download PDF
19. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis
- Author
-
Gorry, MC, primary, Gabbaizedeh, D, additional, Furey, W, additional, Gates, LK, additional, Preston, RA, additional, Aston, CE, additional, Zhang, Y, additional, Ulrich, C, additional, Ehrlich, GD, additional, and Whitcomb, DC, additional
- Published
- 1997
- Full Text
- View/download PDF
20. A gene for hereditary pancreatitis maps to chromosome 7q35
- Author
-
Whitcomb, DC, primary, Preston, RA, additional, Aston, CE, additional, Sossenheimer, MJ, additional, Barua, PS, additional, Zhang, Y, additional, Wong- Chong, A, additional, White, GJ, additional, Wood, PG, additional, Gates, LK, additional, Ulrich, C, additional, Martin, SP, additional, Post, JC, additional, and Ehrlich, GD, additional
- Published
- 1996
- Full Text
- View/download PDF
21. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.
- Author
-
Krishna G, Ma L, Martinho M, Preston RA, O'Mara E, Krishna, G, Ma, L, Martinho, M, Preston, R A, and O'Mara, E
- Abstract
Objectives: Posaconazole is an extended-spectrum triazole with proven efficacy as antifungal treatment and prophylaxis. The marketed oral suspension should be taken with food to maximize systemic absorption. A new solid oral tablet has been developed with improved bioavailability that can be administered without regard to food. The aim of this study was to evaluate rising single- and multiple-dose pharmacokinetics, safety and tolerability of the new tablet.Methods: This was a single-centre, randomized, placebo-controlled, Phase I, rising single- and multiple-dose study of healthy subjects aged 18-65 years who received a posaconazole tablet as 200 mg once daily, 200 mg twice daily or 400 mg once daily. The 24 subjects were studied in two cohorts of 12 subjects each (9 active and 3 placebo).Results: After single or multiple oral dose administration of posaconazole tablets (200 and 400 mg), exposure increased in a dose-related manner. Peak posaconazole concentrations were attained at a median T(max) of 4-5 h. Mean half-life was similar for 200 and 400 mg posaconazole doses (25 and 26 h). The accumulation ratio upon multiple doses over 8 days was ∼3 for 200 and 400 mg once daily and ∼5 for 200 mg twice daily. C(avg) values exceeded 1300 ng/mL. The posaconazole oral tablet was safe and well tolerated, although mild, transient elevations in liver function were reported in some patients.Conclusions: Posaconazole exposure increased in a dose-related manner. The pharmacokinetics of this new solid oral tablet of posaconazole supports the clinical evaluation of once-daily dosing regimens for fungal infections. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
22. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
- Author
-
Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA, Treitel, Michelle, Marbury, Thomas, Preston, Richard A, Triantafyllou, Ilias, Feely, William, O'Mara, Edward, Kasserra, Claudia, Gupta, Samir, and Hughes, Eric A
- Abstract
Background and Objective: Boceprevir is a novel inhibitor of the hepatitis C virus NS3 protease and was recently approved for the treatment of patients with chronic hepatitis C infection. The objective of this study was to evaluate the impact of impaired hepatic or renal function on boceprevir pharmacokinetics and safety/tolerability.Methods: We conducted two open-label, single-dose, parallel-group studies comparing the safety and pharmacokinetics of boceprevir in patients with varying degrees of hepatic impairment compared with healthy controls in one study and patients with end-stage renal disease (ESRD) on haemodialysis with healthy controls in the other. Patients with hepatic impairment (mild [n = 6], moderate [n = 6], severe [n = 6] and healthy controls [n = 6]) received a single dose of boceprevir (400 mg) on day 1, and whole blood was collected at selected timepoints up to 72 hours postdose to measure plasma drug concentrations. Patients with ESRD and healthy subjects received a single dose of boceprevir 800 mg orally on days 1 and 4, with samples for pharmacokinetic analyses collected at selected timepoints up to 48 hours postdose on both days. In addition, 4 hours after dosing on day 4, patients with ESRD underwent haemodialysis with arterial and venous blood samples collected up to 8 hours postdose.Results: In the hepatic impairment study, there was a trend toward increased mean maximum (peak) plasma concentration (C(max)) and area under the plasma concentration-time curve (AUC) of boceprevir with increasing severity of liver impairment. Point estimates for the geometric mean ratio for C(max) ranged from 100% in patients with mild hepatic impairment to 161% in patients with severe hepatic impairment, with the geometric mean ratio for AUC ranging from 91% in patients with mild hepatic impairment to 149% for patients with severe hepatic impairment, relative to healthy subjects. The mean elimination half-life (t(1/2;)) and median time to C(max) (t(max)) values of boceprevir were similar in healthy subjects and patients with hepatic impairment. In the renal impairment study, mean boceprevir C(max) and AUC values were comparable in patients with ESRD and in healthy subjects, with point estimates for the geometric mean ratio of 81% and 90%, respectively, compared with healthy subjects. Mean t(1/2;), median t(max) and mean apparent oral total clearance (CL/F) values were similar in healthy subjects and patients with ESRD. Boceprevir exposure was also similar in patients with ESRD on day 1 (no dialysis) and day 4 (dialysis beginning 4 hours postdose), with point estimates for the geometric mean ratio of C(max) and AUC to the last measurable sampling time (AUC(last)) on day 1 compared with day 4 of 88% and 98%, respectively. Treatment-emergent adverse events were reported in one patient with severe hepatic impairment (mild vomiting) and two patients with ESRD (moderate ventricular extrasystoles, flatulence and catheter thrombosis).Conclusion: In the present studies, the pharmacokinetic properties of boceprevir were not altered to a clinically meaningful extent in patients with impaired liver or renal function. These data indicate that boceprevir dose adjustment is not warranted in patients with impaired hepatic function or ESRD, including those receiving dialysis. Boceprevir is not removed by haemodialysis. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
23. Gender differences in cardiac repolarization following intravenous sotalol administration.
- Author
-
Somberg JC, Preston RA, Ranade V, Cvetanovic I, and Molnar J
- Published
- 2012
24. Developing a safe intravenous sotalol dosing regimen.
- Author
-
Somberg JC, Preston RA, Ranade V, and Molnar J
- Published
- 2010
- Full Text
- View/download PDF
25. Molecular Analysis of Bacterial Pathogens in Otitis Media With Effusion
- Author
-
Aul Jj, Lawrence A. Kingsley, J. Rydquist-White, Magit Ae, Walker Es, J. C. Post, Garth D. Ehrlich, Robert M. Wadowsky, Anderson Kw, Reagan Dr, Larkins-Pettigrew M, and Preston Ra
- Subjects
biology ,business.industry ,medicine.medical_treatment ,General Medicine ,Antimicrobial ,medicine.disease_cause ,biology.organism_classification ,Microbiology ,Haemophilus influenzae ,law.invention ,Myringotomy ,Moraxella catarrhalis ,Otitis ,Effusion ,law ,Streptococcus pneumoniae ,Medicine ,medicine.symptom ,business ,Polymerase chain reaction - Abstract
Objective. —To determine if the polymerase chain reaction (PCR) can detect bacterial DNA in pediatric middle ear effusions that are sterile by standard cultural methods. Design. —Single-center, blinded, comparative study of diagnostic assays. The PCR-based detection systems for Moraxella catarrhalis, Haemophilus influenzae , and Streptococcus pneumoniae were designed and validated using a battery of DNAs obtained from cultured bacteria. Chronic middle ear effusion specimens were collected and comparatively analyzed by culture and the PCR. Setting. —Tertiary care pediatric hospital. Patients. —A total of 97 middle ear effusions were collected from pediatric outpatients at Children's Hospital of Pittsburgh (Pa) during myringotomy and tube placement for chronic otitis media with effusion (duration >3 months). All patients had failed multiple courses of antimicrobial therapy and were diagnosed by a combination of validated otoscopy and tympanograms. Main Outcome Measure. —Differences in the percentage of positive test results between PCR-based assays and culture for M catarrhalis, H influenzae , and S pneumoniae . Results. —Of the 97 specimens of otitis media with effusion, 28 (28.9%) tested positive by both culture and PCR for M catarrhalis, H influenzae , or S pneumoniae . An additional 47 specimens (48%) were PCR positive/culture negative for these three bacterial species. Thus, 75 (77.3%) of the 97 specimens tested PCR positive for one or more of the three test organisms. The minimum number of bacterial genomic equivalents present in the average culture-negative ear was estimated to be greater than 10 4 based on dilutional experiments. Conclusions. —The PCR-based assay systems can detect the presence of bacterial DNA in a significant percentage of culturally sterile middle ear effusions. While this finding is not proof of an active bacterial infectious process, the large number of bacterial genomic equivalents present in the ears is suggestive of an active process. ( JAMA . 1995;273:1598-1604)
- Published
- 1995
- Full Text
- View/download PDF
26. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
- Author
-
Preston RA, Norris PM, Alonso AB, Ni P, Hanes V, and Karara AH
- Published
- 2007
- Full Text
- View/download PDF
27. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
- Author
-
White WB, Pitt B, Preston RA, and Hanes V
- Published
- 2005
28. Current trials of interventions to prevent radiocontrast-induced nephropathy.
- Author
-
Asif A, Garces G, Preston RA, Roth D, Asif, Arif, Garces, Galo, Preston, Richard A, and Roth, David
- Published
- 2005
- Full Text
- View/download PDF
29. University of Miami Division of Clinical Pharmacology Therapeutic Rounds: medications used to treat anorexia in the frail elderly.
- Author
-
Golden AG, Daiello LA, Silverman MA, Llorente M, Preston RA, Golden, Adam G, Daiello, Lori A, Silverman, Michael A, Llorente, Maria, and Preston, Richard A
- Published
- 2003
- Full Text
- View/download PDF
30. Radiocontrast-induced nephropathy.
- Author
-
Asif A, Preston RA, Roth D, Asif, Arif, Preston, Richard A, and Roth, David
- Published
- 2003
- Full Text
- View/download PDF
31. Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus.
- Author
-
Preston RA, Baltodano NM, Alonso AB, and Epstein M
- Abstract
Both ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) are renoprotective beyond their effects on blood pressure (BP), but their widespread use is limited by their tendency to provoke hyperkalemia. The comparative effects of ACEI and ARB on potassium handling have not been investigated. The objective of this study was to determine whether there are differences in dynamic renal potassium handling between ACEI and ARB in response to an oral potassium challenge. This was a randomized crossover study of candesartan versus lisinopril titrated to control BP followed by an inpatient study of renal potassium handling in 24 hypertensive patients with type II diabetes mellitus (DMII) and preserved renal function. Following an oral potassium challenge (0.75 mmol/kg), differences in hourly serum K (mmol/L), rate of urinary potassium excretion (UkV, micromol/min), and fractional excretion of potassium (FEK) were assessed by repeated-measures ANOVA. Hourly UkV(p = .45) and FEK (p = .19) were similar for candesartan and lisinopril, although FEK at 2 hours for candesartan tended to exceed that for lisinopril (.34 [.04] vs. .26 [.03]) and approached significance (p = .096). UkVfor candesartan at hour 2 was 177 (26) and 121 (21) for lisinopril and also approached significance (p = .10). Serial serum potassium did not differ (p = .70). No statistical differences were discovered in renal potassium handling between candesartan and lisinopril in patients with DMII and preserved renal function. Whether there are differences between the drug classes in renal impairment remains to be determined. [ABSTRACT FROM AUTHOR]
- Published
- 2002
32. Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus.
- Author
-
Preston RA, Chung M, Gaffney M, Alonso A, Baltodano NM, and Epstein M
- Abstract
Recent clinical trials aimed at attenuating complications in diabetes mellitus have generated interest in the impact of drug formulation and altered pharmacokinetics and pharmacodynamics in diabetes. Specifically, it has been proposed that the diabetic state may alter the pharmacokinetics of several cardiovascular drugs, including some calcium antagonists. The present study investigates the effects of diabetes mellitus on the pharmacokinetics and pharmacodynamics of amlodipine in hypertensive subjects with and without diabetes mellitus to determine whether the diabetic state alters these parameters. This trial consisted of a 2-week placebo washout phase, a 2-week titration phase, and a 2-week maintenance phase. Study patients included 18 hypertensive patients with type II diabetes mellitus and 10 nondiabetic hypertensive patients. Blood samples were collected after administration of amlodipine and AUC, Cmax, and tmax were determined. The acute 24-hour pharmacodynamic response to amlodipine was assessed by blood pressure and telemetric heart rate measurements. There were no significant differences for either amlodipine 5 or 10 mg in AUC (p = 0.40 for 5 mg; p = 0.59 for 10 mg), Cmax (p = 0.41 for 5 mg; p = 0.45 for 10 mg), and tmax (p = 0.79 for 5 mg; p = 0.67 for 10 mg) between diabetic and nondiabetic hypertensive subjects. Similarly, the 24-hour pharmacodynamic effects of amlodipine on systolic blood pressure, diastolic blood pressure, and heart rate did not differ between diabetic and nondiabetic subjects as assessed by repeated-measures analysis of variance. Because of the theoretical basis for anticipating that diabetes mellitus may provoke important pharmacokinetic and pharmacodynamic alterations, our study provides an important database in clearly demonstrating that the diabetic milieu did not alter the pharmacokinetics or pharmacodynamics of amlodipine. [ABSTRACT FROM AUTHOR]
- Published
- 2001
33. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs cooperative study.
- Author
-
Preston RA, Materson BJ, Reda DJ, and Williams DW
- Published
- 2000
- Full Text
- View/download PDF
34. Management update. Prevention of diabetic nephropathy.
- Author
-
Materson BJ and Preston RA
- Published
- 1997
35. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
- Author
-
Materson BJ, Reda DJ, Preston RA, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, and Lakshman R
- Published
- 1995
- Full Text
- View/download PDF
36. Lack of major involvement of human uroplakin genes in vesicoureteral reflux: Implications for disease heterogeneity
- Author
-
Fang Ming Deng, Ellen Shapiro, Xiang Y. Ye, Judith A. Goodship, Fen Z. Hu, Preston Ra, Monika H. Hermanns, Sally Feather, Harry Ostrer, Jordan Gitlin, Feng-Xia Liang, Anthony Atala, Stuart B. Bauer, Tung-Tien Sun, Judith D. Goldberg, Andy Lee, Adrian S. Woolf, Francis X. Schneck, Garth D. Ehrlich, Katrin E. Jones, Xue-Ru Wu, Alan B. Retik, Victoria Wright, Cathy Mendelsohn, Songshan Jiang, Timothy H.J. Goodship, Jun Yu, and Sue Malcolm
- Subjects
Proband ,Pathology ,uroplakin ,030232 urology & nephrology ,Gene Expression ,Bioinformatics ,urologic and male genital diseases ,Polymerase Chain Reaction ,Exon ,Mice ,0302 clinical medicine ,Missense mutation ,0303 health sciences ,education.field_of_study ,Mice, Inbred BALB C ,Uroplakin III ,Alanine ,Membrane Glycoproteins ,Chromosome Mapping ,Exons ,female genital diseases and pregnancy complications ,3. Good health ,Nephrology ,Uroplakin II ,medicine.medical_specialty ,Guanine ,Genotype ,Proline ,Population ,Molecular Sequence Data ,Mutation, Missense ,Single-nucleotide polymorphism ,Vesicoureteral reflux ,Polymorphism, Single Nucleotide ,Frameshift mutation ,Nephropathy ,03 medical and health sciences ,Cytosine ,hydronephrosis ,medicine ,Animals ,Humans ,Genetic Predisposition to Disease ,education ,Uroplakin Ia ,030304 developmental biology ,Uroplakin Ib ,Vesico-Ureteral Reflux ,vesicoureteral reflux (VUR) ,Base Sequence ,business.industry ,Membrane Proteins ,urothelium ,medicine.disease ,Embryo, Mammalian ,Introns ,Amino Acid Substitution ,Case-Control Studies ,business ,Thymine - Abstract
Lack of major involvement of human uroplakin genes in vesicoureteral reflux: Implications for disease heterogeneity. background primary vesicoureteral reflux (vur) is a hereditary disorder characterized by the retrograde flow of urine into the ureters and kidneys. it affects about 1% of the young children and is thus one of the most common hereditary diseases. its associated nephropathy is an important cause of end-stage renal failure in children and adults. recent studies indicate that genetic ablation of mouse uroplakin (up) iii gene, which encodes a 47 kd urothelial-specific integral membrane protein forming urothelial plaques, causes vur and hydronephrosis. methods to begin to determine whether mutations in up genes might play a role in human vur, we genotyped all four up genes in 76 patients with radiologically proven primary vur by polymerase chain reaction (pcr) amplification and sequencing of all their exons plus 50 to 150 bp of flanking intronic sequences. results eighteen single nucleotide polymorphisms (snps) were identified, seven of which were missense, with no truncation or frame shift mutations. since healthy relatives of the vur probands are not reliable negative controls for vur, we used a population of 90 race-matched, healthy individuals, unrelated to the vur patients, as controls to perform an association study. most of the snps were not found to be significantly associated with vur. however, snp1 of up ia gene affecting a c to t conversion and an ala7val change, and snp7 of up iii affecting a c to g conversion and a pro154ala change, were marginally associated with vur (both p = 0.08). studies of additional cases yielded a second set of data that, in combination with the first set, confirmed a weak association of up iii snp7 in vur ( p = 0.036 adjusted for both subsets of cases vs. controls). conclusion such a weak association and the lack of families with simple dominant Mendelian inheritance suggest that missense changes of uroplakin genes cannot play a dominant role in causing VUR in humans, although they may be weak risk factors contributing to a complex polygenic disease. The fact that no truncation or frame shift mutations have been found in any of the VUR patients, coupled with our recent finding that some breeding pairs of UP III knockout mice yield litters that show not only VUR, but also severe hydronephrosis and neonatal death, raises the possibility that major uroplakin mutations could be embryonically or postnatally lethal in humans.
- Full Text
- View/download PDF
37. Development and validation of a multiplex PCR-based assay for the upper respiratory tract bacterial pathogens haemophilus influenzae, streptococcus pneumoniae, and moraxella catarrhalis
- Author
-
Post, JC, White, GJ, Aul, JJ, Zavoral, T, Wadowsky, RM, Zhang, Y, Preston, RA, and Ehrlich, GD
- Abstract
Background:Conventional simplex polymerase chain reaction (PCR)-based assays are limited in that they only provide for the detection of a single infectious agent. Many clinical diseases, however, present in a nonspecific, or syndromic, fashion, thereby necessitating the simultaneous assessment of multiple pathogens. Panel-based molecular diagnostic testing can be accomplished by the development of multiplex PCR-based assays, which can detect, individually or severally, different pathogens that are associated with syndromic illness. As part of a larger program of panel development, an assay that can simultaneously detect Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis was developed. These organisms were chosen as they are the most common bacterial pathogens associated with both the acute and chronic forms of otitis media; they are also responsible for a high percentage of sinus infections in both children and adults. In addition, H. influenzae and S. pneumoniae are commonly associated with septic meningitits.
- Published
- 1996
- Full Text
- View/download PDF
38. Thermal structure in the Venus middle cloud layer
- Author
-
Linkin, Vm, Lipatov, An, Shurupov, Aa, Ignatova, Sp, Frank, Ga, Khlyustova, Li, Terterashvili, Av, Kerzhanovich, Vv, Blamont, Je, Malique, C., Seiff, A., Ragent, B., Young, Re, Elson, Ls, Preston, Ra, Ingersoll, Ap, and David Crisp
- Abstract
Thermal structure measurements obtained by the two Vega balloons show the Venus atmosphere in the middle cloud layer to be near-adiabatic, on the whole; but discrete air masses are present that differ slightly from one another in potential temperature and entropy. The Vega 1 temperatures are 6.5 K warmer than measured by Vega 2 at given pressures. Measurements taken by the Vega 2 lander on descent through these levels agree with the Vega 2 balloon data.
- Published
- 1986
39. IMPLICATIONS OF PRELIMINARY VEGA BALLOON RESULTS FOR THE VENUS ATMOSPHERE DYNAMICS
- Author
-
Blamont, Je, Sagdeev, Rz, Linkin, Vm, Kerzhanovich, Vv, David Crisp, Ingersoll, Ap, Elson, Ls, Preston, Ra, Golitsyn, Gs, Ivanov, Vn, Ragent, B., Seiff, A., and Young, Re
- Abstract
The typical 1-2 m/sec vertical winds encountered by the Vega balloons probably result from thermal convection. The consistent 6.5-kelvin differential between the Vega 1 and Vega 2 temperatures is attributable to disturbances of synoptic or planetary scale. According to the Doppler tracking the winds were stronger than on earlier missions, perhaps because of solar thermal tides. The motions of Vega 2 may have been affected by waves from mountainous terrain.
40. Placebo-associated blood pressure response and adverse effects.
- Author
-
Materson, BJ, Preston, RA, Reda, DJ, and Williams, D
- Published
- 1999
- Full Text
- View/download PDF
41. Hypertension in haitians: Clinical characteristics of patients with JNC-V stage 3 and 4 hypertension
- Author
-
Preston, RA, Materson, BJ, Yoham, MA, and Anapol, H
- Published
- 1995
- Full Text
- View/download PDF
42. Hypertension in haitians: Pilot survey of a public teaching hospital multispecialty clinic
- Author
-
Preston, RA, Materson, BJ, Yoham, MA, and Anapol, H
- Published
- 1995
- Full Text
- View/download PDF
43. Hypertension in hispanics: Pilot survey of a public teaching hohspital multi-specialty clinic
- Author
-
Preston, RA, Materson, BJ, Yoham, MA, Caralis, PV, and Anapol, H
- Published
- 1995
- Full Text
- View/download PDF
44. H5 - Hypertension in haitians: Pilot survey of a public teaching hospital multispecialty clinic
- Author
-
Preston, RA, Materson, BJ, Yoham, MA, and Anapol, H
- Published
- 1995
- Full Text
- View/download PDF
45. H4 - Hypertension in haitians: Clinical characteristics of patients with JNC-V stage 3 and 4 hypertension
- Author
-
Preston, RA, Materson, BJ, Yoham, MA, and Anapol, H
- Published
- 1995
- Full Text
- View/download PDF
46. H3 - Hypertension in hispanics: Pilot survey of a public teaching hohspital multi-specialty clinic
- Author
-
Preston, RA, Materson, BJ, Yoham, MA, Caralis, PV, and Anapol, H
- Published
- 1995
- Full Text
- View/download PDF
47. Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics.
- Author
-
Li C, Preston RA, Dumas E, Beelen A, and Marbury TC
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Triazoles pharmacokinetics, Triazoles administration & dosage, Liver Diseases metabolism, Protein Kinase Inhibitors pharmacokinetics, Protein Kinase Inhibitors administration & dosage, Lactones pharmacokinetics, Lactones administration & dosage, Adult, Area Under Curve, Lung Neoplasms drug therapy, Pyrimidines, Pyrroles, Antineoplastic Agents pharmacokinetics, Antineoplastic Agents adverse effects, Antineoplastic Agents administration & dosage
- Abstract
Trilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4 and 6 inhibitor approved for reducing the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small cell lung cancer receiving a platinum/etoposide-containing or topotecan-containing regimen. No dose adjustment is recommended for participants with mild hepatic impairment (HI) based on previous population pharmacokinetic (PK) analysis. This open-label, parallel-group study examined the impact of moderate and severe HI on the PK of trilaciclib. The study employed a reduced study design. Participants with moderate (Child-Pugh B, n = 8) and severe (Child-Pugh C, n = 5) HI and matched healthy controls (n = 11) received a single intravenous dose of trilaciclib 100 mg/m
2 . The unbound fraction of trilaciclib was comparable between the HI groups and the matched healthy control group. The unbound trilaciclib extent of exposure (i.e., area under the concentration-time curve) in participants with moderate and severe HI was ∼40% and ∼60% higher, respectively, compared with healthy matched controls based on Child-Pugh classification. Ad hoc analysis using National Cancer Institute classification showed similar results. The US Food and Drug Administration-approved trilaciclib dose of 240 mg/m2 should be reduced by ∼30%, to 170 mg/m2 , for patients with moderate or severe HI., (© 2024 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.)- Published
- 2024
- Full Text
- View/download PDF
48. Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study.
- Author
-
Marbury T, El-Hashimy M, Blumenstein L, Letellier F, Sengupta T, Lorenzo S, and Preston RA
- Abstract
The pharmacokinetics (PK) and safety of single-dose alpelisib (300 mg) were assessed in participants with moderate to severe hepatic impairment (n = 6 each) compared with their matching healthy controls (n = 11). Blood samples were collected upto 144 hours post-dose and evaluated by liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay. The primary PK parameters (maximum plasma concentration [C
max ], area under the curve [AUC]inf and AUClast ) and secondary PK parameters (AUC0-t , apparent total body clearance [CL/F], apparent volume of distribution [Vz/F], time of maximum observed concentration [Tmax ], and half-life [T1/2 ]) of oral alpelisib 300 mg were determined from individual plasma concentration-time profiles using non‑compartmental analysis. Cmax of alpelisib decreased by approximately 17% in the moderate hepatic impairment group vs. the healthy control group (geometric mean ratio; GMR [90% confidence interval; CI], 0.833 [0.530, 1.31]). Cmax in the severe hepatic impairment group was comparable to that of the healthy control group (GMR [90% CI], 1.00 [0.636, 1.58]). AUClast for alpelisib decreased by approximately 27% in the moderate hepatic impairment group vs. the healthy control group (GMR [90% CI], 0.726 [0.487, 1.08]). AUClast was 26% higher in the severe hepatic impairment group compared with the healthy control group (GMR [90% CI], 1.26 [0.845, 1.87]). Overall, 3 participants (13.0%) experienced at least 1 adverse event which were either grade 1 or 2. Adverse events did not lead to study drug discontinuation. No grade 3 or 4 adverse events, serious adverse events or deaths were reported. The results indicate that a single dose of alpelisib was well tolerated in this study population. There was no significant impact of moderate or severe hepatic impairment on the exposure of alpelisib., Competing Interests: Competing Interests: Dr. Marbury is an employee and equity owner of Orlando Clinical Research Center. Dr. El-Hashimy is an employee of Novartis Pharmaceutical Corporation and holds Novartis stock options. Dr. Blumenstein is an employee of Novartis Institutes for Biomed. Research and holds Novartis stock options. Letellier is an employee of Novartis Pharma S.A.S and holds Novartis stock options. Dr. Sengupta is an employee of Novartis Healthcare Pvt. Ltd. Lorenzo is an employee of Novartis Pharma AG and holds Novartis shares Dr. Preston reports grants from Novartis during the conduct of the study., (© The author(s).)- Published
- 2023
- Full Text
- View/download PDF
49. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.
- Author
-
Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O, LaBadie RR, Binks M, Chan PLS, Demers N, Corrigan B, and Damle B
- Subjects
- Antiviral Agents adverse effects, Enzyme Inhibitors, Humans, Protease Inhibitors, Ritonavir adverse effects, Renal Insufficiency, COVID-19 Drug Treatment
- Abstract
Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of coronavirus disease 2019 (COVID-19) adverse outcomes among patients at increased risk of progression to severe disease, including patients with chronic kidney disease. Because nirmatrelvir is eliminated by the kidneys when given with ritonavir, this phase I study evaluated the effects of renal impairment on pharmacokinetics, safety, and tolerability of nirmatrelvir/ritonavir. Participants with normal renal function (n = 10) or mild, moderate, or severe renal impairment (n = 8 each) were administered a single 100-mg nirmatrelvir dose with 100 mg ritonavir given 12 hours before, together with and 12 and 24 hours after the nirmatrelvir dose. Systemic nirmatrelvir exposure increased with increasing renal impairment, with mild, moderate, and severe renal impairment groups having respective adjusted geometric mean ratio areas under the plasma concentration-time profile from time 0 extrapolated to infinite time of 124%, 187%, and 304% vs. the normal renal function group. Corresponding ratios for maximum plasma concentration were 130%, 138%, and 148%. Apparent clearance was positively correlated with estimated glomerular filtration rate, and geometric mean renal clearance values were particularly lower for the moderate (47% decrease) and severe (80% decrease) renal impairment groups vs. the normal renal function group. Nirmatrelvir/ritonavir exhibited an acceptable safety profile; treatment-related adverse events were mild in severity, and there were no significant findings regarding laboratory measurements, vital signs, or electrocardiogram assessments. These findings led to a dose reduction recommendation for nirmatrelvir/ritonavir in patients with moderate renal impairment (150/100 mg nirmatrelvir/ritonavir instead of 300/100 mg twice daily for 5 days). NCT04909853., (© 2022 Pfizer Inc. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2022
- Full Text
- View/download PDF
50. Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
- Author
-
Xu Y, Izumi R, Nguyen H, Kwan A, Kuo H, Madere J, Slatter JG, Podoll T, Vishwanathan K, Marbury T, Smith W, Preston RA, Sharma S, and Ware JA
- Subjects
- Adult, Area Under Curve, Benzamides adverse effects, Humans, Pyrazines adverse effects, Liver Diseases metabolism
- Abstract
Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact of hepatic impairment (HI) on acalabrutinib pharmacokinetics (PK) and safety at a single 50-mg dose in fasted subjects. This study was divided into 2 parts: study 1, an open-label, parallel-group study in Child-Pugh class A or B subjects and healthy subjects; and study 2, an open-label, parallel-group study in Child-Pugh class C subjects and healthy subjects. Baseline characteristics and safety profiles were similar across groups. Acalabrutinib exposure (area under the plasma concentration-time curve) increased slightly (1.90- and 1.48-fold) in subjects with mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment compared with healthy subjects. In severe hepatic impairment (Child-Pugh class C), acalabrutinib exposure (area under the plasma concentration-time curve and maximum plasma concentration) increased ≈5.0- and 3.6-fold, respectively. Results were consistent across total and unbound exposures. Severe hepatic impairment did not impact total/unbound metabolite (ACP-5862) exposures; the metabolite-to-parent ratio decreased to 0.6 to 0.8 (vs 3.1-3.6 in healthy subjects). In summary, single oral dose of 50-mg acalabrutinib was safe and well tolerated in subjects with mild, moderate, and severe hepatic impairment and in healthy control subjects. In subjects with severe hepatic impairment, mean acalabrutinib exposure increased by up to 5-fold and should be avoided. Acalabrutinib does not require dose adjustment in patients with mild or moderate hepatic impairment., (© 2021 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.